Capricor Therapeutics, Inc. (CAPR), is a renowned biotechnology company that is dedicated to the discovery, development, and commercialization of first-in-class cell- and exosome-based therapeutics for treating and preventing a multitude of diseases. Among the diseases targeted by the company include Duchenne muscular dystrophy (DMD), cardiac tissues damaged through acute myocardial infarctions, and complications arising from COVID-19.
The California-based company's proprietary lead candidate, CAP-1002, an "off-the-shelf" cardiac cell therapy, has been spotlighted as a promising treatment for patients afflicted with DMD; a fatal genetic disorder characterized by progressive muscular weakness due to the breakdown and loss of muscle cells. Currently, there are no universally effective treatments for DMD, making the progress of CAPR's potential breakthrough highly noteworthy.
Moreover, this versatile revolutionary technology is also believed to have applications in repairing heart tissues that are damaged by poor blood flow, usually a result of heart attacks. Besides, CAPR’s research has been diverted towards combating COVID-19 through their exosome technology platform, named CAP-1002, to block ACE2 and S-protein interaction, which is a key gateway used by the COVID-19 virus to get into cells.
Since its inception, CAPR has been at the forefront of innovative cellular therapies and is committed to groundbreaking research in regenerative medicine. Its efforts to design and develop unique treatments to address severe medical conditions with unmet medical needs have positioned it as a leader in its field. To this end, the company collaborates with various scientific and medical communities worldwide to share knowledge, leveraging its resources and expertise in a global effort to combat devastating illnesses.
Furthermore, demonstrating its commitment to excellence, CAPR's work has garnered support from respected sources such as the National Institutes of Health and the California Institute for Regenerative Medicine. It has also entered strategic licensing agreements with tech giants like Cedars-Sinai Medical Center, further proving its dedication to innovation, collaboration, and groundbreaking advancements in biopharmaceutical sciences.
Capricor Therapeutics, Inc. is publicly traded on NASDAQ under the symbol CAPR, emphasizing its position as a key player in the biotechnology industry. The company's robust portfolio and extensive experience in cell biology and genetic therapies make it a strong contender in the ever-evolving healthcare industry. In the hands of a seasoned team of medical professionals, researchers, and business leaders, CAPR continues to forge new pathways in cell and gene therapy, aiming to make significant contributions to science and society.